Sarclisa Accepts for FDA Priority Review for the Treatment o

The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for the investigational use of Sarclisa in combination with bortezomib,...

Related Keywords

United States , American , , Drug Administration , European Union , European Hematology Association , American Society Of Clinical Oncology , Priority Review , Biologics License Application , Clinical Oncology , Annual Meeting , Hematology Association , Nonproprietary Naming , Biological Products Guidance ,